secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001104659-24-002631
Event type: debt
Sentiment:  negative
Materiality: 0.65
Item codes: 1.01, 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Pharmaceuticals restructures debt; issues stock and warrants for $2M loan assignment
--------------------------------------------------------------------------------

- Entered Fifth Amendment to Hercules Loan Agreement; $2M Tranche 1B Advance assigned to SD MF 4 LLC.
- Issued 157,138 shares of common stock, pre-funded warrant for 471,508 shares, and warrant for 150,000 shares to assignee in exchange for debt assumption.
- No cash proceeds from equity issuance; loan financial covenant for minimum cash balance removed for assigned tranche.
- Interest may be paid in-kind on Tranche 1B; principal amortization deferrable at assignee's option.
- Company must file resale registration statement within 15 days; exercise prices: pre-funded $0.001, additional $1.18.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465924002631/0001104659-24-002631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465924002631/tm242562d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer